Cargando…
Cutaneous Sarcoidosis: An Uncommon Side Effect of Pegylated Interferon and Ribavirin Use for Chronic Hepatitis C
The treatment of chronic hepatitis C (CHC) has evolved in the past 15 years and combination of pegylated interferon plus ribavirin is its current standard therapy. However, several side effects are commonly observed and frequently lead to transient or definitive interruption of treatment. Although s...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2988931/ https://www.ncbi.nlm.nih.gov/pubmed/21103255 http://dx.doi.org/10.1159/000251664 |
_version_ | 1782192309217001472 |
---|---|
author | Martins, Elson Vidal Gaburri, Ana Karla Gaburri, Debora Sementilli, Angelo |
author_facet | Martins, Elson Vidal Gaburri, Ana Karla Gaburri, Debora Sementilli, Angelo |
author_sort | Martins, Elson Vidal |
collection | PubMed |
description | The treatment of chronic hepatitis C (CHC) has evolved in the past 15 years and combination of pegylated interferon plus ribavirin is its current standard therapy. However, several side effects are commonly observed and frequently lead to transient or definitive interruption of treatment. Although sarcoidosis in its systemic or cutaneous form is a very rare side effect in such circumstances, some cases have been reported even with conventional interferon. This brief review of the literature and description of a case of sarcoidosis occurring in a tattoo and a scar patient's face, during treatment with pegylated interferon alpha-2b plus ribavirin, is an educative report directed in special to dermatologists. The lesion improved after drug interruption and recurred after retreatment with pegylated interferon alpha-2a. We conclude that this side effect must call the attention of doctors to seek for the diagnosis and therapy as soon as possible in such circumstances. No differences were noticed neither with alpha-2a nor alpha-2b pegylated interferon employment. |
format | Text |
id | pubmed-2988931 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-29889312010-11-22 Cutaneous Sarcoidosis: An Uncommon Side Effect of Pegylated Interferon and Ribavirin Use for Chronic Hepatitis C Martins, Elson Vidal Gaburri, Ana Karla Gaburri, Debora Sementilli, Angelo Case Rep Gastroenterol Published: November 2009 The treatment of chronic hepatitis C (CHC) has evolved in the past 15 years and combination of pegylated interferon plus ribavirin is its current standard therapy. However, several side effects are commonly observed and frequently lead to transient or definitive interruption of treatment. Although sarcoidosis in its systemic or cutaneous form is a very rare side effect in such circumstances, some cases have been reported even with conventional interferon. This brief review of the literature and description of a case of sarcoidosis occurring in a tattoo and a scar patient's face, during treatment with pegylated interferon alpha-2b plus ribavirin, is an educative report directed in special to dermatologists. The lesion improved after drug interruption and recurred after retreatment with pegylated interferon alpha-2a. We conclude that this side effect must call the attention of doctors to seek for the diagnosis and therapy as soon as possible in such circumstances. No differences were noticed neither with alpha-2a nor alpha-2b pegylated interferon employment. S. Karger AG 2009-11-21 /pmc/articles/PMC2988931/ /pubmed/21103255 http://dx.doi.org/10.1159/000251664 Text en Copyright © 2009 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No-Derivative-Works License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions. |
spellingShingle | Published: November 2009 Martins, Elson Vidal Gaburri, Ana Karla Gaburri, Debora Sementilli, Angelo Cutaneous Sarcoidosis: An Uncommon Side Effect of Pegylated Interferon and Ribavirin Use for Chronic Hepatitis C |
title | Cutaneous Sarcoidosis: An Uncommon Side Effect of Pegylated Interferon and Ribavirin Use for Chronic Hepatitis C |
title_full | Cutaneous Sarcoidosis: An Uncommon Side Effect of Pegylated Interferon and Ribavirin Use for Chronic Hepatitis C |
title_fullStr | Cutaneous Sarcoidosis: An Uncommon Side Effect of Pegylated Interferon and Ribavirin Use for Chronic Hepatitis C |
title_full_unstemmed | Cutaneous Sarcoidosis: An Uncommon Side Effect of Pegylated Interferon and Ribavirin Use for Chronic Hepatitis C |
title_short | Cutaneous Sarcoidosis: An Uncommon Side Effect of Pegylated Interferon and Ribavirin Use for Chronic Hepatitis C |
title_sort | cutaneous sarcoidosis: an uncommon side effect of pegylated interferon and ribavirin use for chronic hepatitis c |
topic | Published: November 2009 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2988931/ https://www.ncbi.nlm.nih.gov/pubmed/21103255 http://dx.doi.org/10.1159/000251664 |
work_keys_str_mv | AT martinselsonvidal cutaneoussarcoidosisanuncommonsideeffectofpegylatedinterferonandribavirinuseforchronichepatitisc AT gaburrianakarla cutaneoussarcoidosisanuncommonsideeffectofpegylatedinterferonandribavirinuseforchronichepatitisc AT gaburridebora cutaneoussarcoidosisanuncommonsideeffectofpegylatedinterferonandribavirinuseforchronichepatitisc AT sementilliangelo cutaneoussarcoidosisanuncommonsideeffectofpegylatedinterferonandribavirinuseforchronichepatitisc |